COVID-19 Guidance from the GenTAC Alliance

COVID-19 Guidance from the Marfan Foundation

In light of the current public health crisis due to COVID-19, The Marfan Foundation is providing regular updates for the Marfan, VEDS, Loeys-Dietz, and related condition community. Their Professional Advisory Board has collaborated with us to bring you the best medical information on COVID-19 in relation to our community. Click here to visit The Marfan Foundation page for COVID-19 updates.

Guidance on ACE- Inhibitors and COVID-19

There have been theoretical concerns related to the use of ACE-inhibitors and ARBS in the setting of COVID 19. The ACC is recommending no changes in medical management at this time. Click here for the link to current ACC recommendations (published 3/17). 

Common ARB’s: losartan, irbesartan, valsartan, olmesartan, telmisartan
Common ACE Inhibitors: lisinopril, enalapril, captopril, ramipril

Tip of the Week

In this week's tip, Dr. Kim Eagle discusses the importance of continuing use of prescribed angiotosin receptor blocking medication (such as losartan, irbesartan, valsartan, olmesartan, telmisartan) and ACE inhibitors (lisinopril, enalapril, captopril, ramipriland), despite early reports that these medications may increase risk or severity of COVID-19.

Influenza Infection and Aortic Dissection

GenTAC Alliance researchers have contributed to a new article describing their isolation of influenza virus from the wall of dissected aorta. This article discusses the possible interactions between aortic dissection and influenza virus and possibility of winter spikes in acute aortic dissections being connected to influenza virus and not just the cold weather. 

View Article